3.3(top 10%)
impact factor
3.1K(top 10%)
papers
73.8K(top 5%)
citations
114(top 5%)
h-index
3.5(top 10%)
impact factor
3.3K
all documents
76.9K
doc citations
172(top 5%)
g-index

Top Articles

#TitleJournalYearCitations
1Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene TherapyJournal of Immunotherapy2013953
2Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic AdenocarcinomaJournal of Immunotherapy2010950
3Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and HypophysitisJournal of Immunotherapy2007656
4Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma PatientsJournal of Immunotherapy2003598
5Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic CancerJournal of Immunotherapy2013460
6Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2bJournal of Immunotherapy2010420
7IL-7 Administration to Humans Leads to Expansion of CD8+ and CD4+ Cells but a Relative Decrease of CD4+ T-Regulatory CellsJournal of Immunotherapy2006397
8Induction of Cytokine Production from Human Monocytes Stimulated with AlginateJournal of Immunotherapy1991347
9Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic MelanomaJournal of Immunotherapy2001337
10Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen ReceptorJournal of Immunotherapy2009336
11PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic TumorsJournal of Immunotherapy2015333
12A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic MelanomaJournal of Immunotherapy2002326
13Cytotoxic T-Lymphocyte-Associated Antigen-4 Blockage Can Induce Autoimmune Hypophysitis in Patients With Metastatic Melanoma and Renal CancerJournal of Immunotherapy2005315
14Vitiligo in Patients with MelanomaJournal of Immunotherapy1996308
15Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma PatientsJournal of Immunotherapy2009301
16Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to ImmunotherapyJournal of Immunotherapy2013299
17Cancer and Inflammation: Promise for Biologic TherapyJournal of Immunotherapy2010293
18Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor ActivityJournal of Immunotherapy2011281
19Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With MelanomaJournal of Immunotherapy2005270
20PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion VaccineJournal of Immunotherapy2011270
21Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell TherapyJournal of Immunotherapy2009269
22PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma CancerJournal of Immunotherapy2012269
23Human Immune Respone to Monoclonal AntibodiesJournal of Immunotherapy1994267
24A Clinical Development Paradigm for Cancer Vaccines and Related BiologicsJournal of Immunotherapy2007260
25The Role of Extracellular Spacer Regions in the Optimal Design of Chimeric Immune ReceptorsJournal of Immunotherapy2005258
26Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic MelanomaJournal of Immunotherapy2006246
27Immune Suppression in the Tumor MicroenvironmentJournal of Immunotherapy2006242
28Sorting Through SubsetsJournal of Immunotherapy2012237
29Minimally Cultured Tumor-infiltrating Lymphocytes Display Optimal Characteristics for Adoptive Cell TherapyJournal of Immunotherapy2008236
30Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T CellsJournal of Immunotherapy2010236
31Tumor-Induced Immune Dysfunctions Caused by Myeloid Suppressor CellsJournal of Immunotherapy2001234
32Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With GlioblastomaJournal of Immunotherapy2019231
33The Biologic Effects of C225, A Chimeric Monoclonal Antibody to the EGFR, on Human Prostate CarcinomaJournal of Immunotherapy1996221
34Histologic Predictors of Renal Cell Carcinoma Response to Interleukin-2-Based TherapyJournal of Immunotherapy2005217
35Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNAJournal of Immunotherapy2008216
36Dendritic Cells Loaded With Killed Allogeneic Melanoma Cells can Induce Objective Clinical Responses and MART-1 Specific CD8+ T-cell ImmunityJournal of Immunotherapy2006214
37Cytokines and Immune Response in the Tumor MicroenvironmentJournal of Immunotherapy2001212
38Identification of T-Cell EpitopesJournal of Immunotherapy1993210
39Reversal of Tumor-Induced Immunosuppression: A New Approach to Cancer TherapyJournal of Immunotherapy1997202
40Adoptive Transfer of EBV-specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal CarcinomaJournal of Immunotherapy2010201
41Vaccination of Glioma Patients with Fusions of Dendritic and Glioma Cells and Recombinant Human Interleukin 12Journal of Immunotherapy2004199
42CD4+CD25+ T Regulatory Cells, Immunotherapy of Cancer, and Interleukin-2Journal of Immunotherapy2005199
43Persistence of Multiple Tumor-Specific T-Cell Clones Is Associated with Complete Tumor Regression in a Melanoma Patient Receiving Adoptive Cell Transfer TherapyJournal of Immunotherapy2005198
44Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-β ReceptorJournal of Immunotherapy2008197
45Myeloid-derived Suppressor Cells in Cancer PatientsJournal of Immunotherapy2012195
46Regulatory (FoxP3+) T-cell Tumor Infiltration Is a Favorable Prognostic Factor in Advanced Colon Cancer Patients Undergoing Chemo or ChemoimmunotherapyJournal of Immunotherapy2010190
47Depletion of CD4+CD25+ Regulatory Cells Augments the Generation of Specific Immune T Cells in Tumor-Draining Lymph NodesJournal of Immunotherapy2002189
48Combination of Conformal Radiotherapy and Intratumoral Injection of Adoptive Dendritic Cell Immunotherapy in Refractory HepatomaJournal of Immunotherapy2005189
49Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell MalignanciesJournal of Immunotherapy2001188
50Identification of Multiple Antigens Recognized by Tumor-Infiltrating Lymphocytes From a Single Patient: Tumor Escape by Antigen Loss and Loss of MHC ExpressionJournal of Immunotherapy2004188